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S_ary We examined the microvascular effects of competitive nitric oxide synthase (NOS) inhibition with
NM-monomethyl-L-arginine (MeArg), followed by L-argliine, on R3230Ac mammary adenocarcinoma per-
fusion. In window preparations containing tumours, superfusion of 50 LM MeArg reduced diameters ofcentral
tumour venules by 13%, of peripheral tumour venules by 17% and of normal venules near tumours by 16%
from baseline. MeArg reduced red blood cell (RBC) veloity in central tumour venules by 25%, and increased
intermittent flow and stasis frequency by 20% in central tumour venules. Subsequent superfusion of 200 M
L-arginine Wd not restore diameters or RBC velocity of any tumour preparation venules, and decreased length
density in both central tumour venules and penpheral tumour venules. In contrast, MeArg reduced control
preparation venule diameter by 30% and RBC velocity by 66%, but did not decrease length density or
increase intermittent flow or stasis frequency. Unlke tumour preparation venules, L-arginine restored control
venule diameters and velocities. NOS inhibition reduces both tumour and control venule perfusion, but the
effect is blunted in the vicnity of tumours, possibly because of increased NOS levels. Perfusion can be
subsequently restored in control, but not tumour, venules with L-argnine. Tumour NOS inhibition, followed
by normal tissue rescue with L-arginine, may provide a novel means to achieve the goal of selective tumour
hypoxia.
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A relatively new and novel approach to solid tumour therapy
has involved the induction of tumour hypoxia following the
administration of drugs that are seectively cytotoxic to
hypoxic cells (Chaplin and Acker, 1987; Brown and Koong,
1991). It has been suggested that systemic administration ofa
hypoxic cell cytotoxin, followed by a drug that selectively
reduces tumour blood flow, would augment cytotoxicity of
such agents by trapping the cytotoxic agent within the
tumour mass and increase their cytotoxicity via induction of
hypoxia (Chaplin, 1989); this approach has recently been
validated using NoArg and RB6145 in a transplantable
murine tumour system (Wood et al., 1994). Selective reduc-
tion of tumour blood flow could also lead to enhanc
efficacy of hyperthermia because of reduced heat transfer,
resulting in improved temperatures during heating and in-
creased cytotoxicity ofhypoxic, acidotic cells (Dewhirst et al.,
1990).
Solid tumours are a heterogeneous population of cell
types, including tumour, vascular and infiltrating immune
cells. GeneraDly speaking, tumour blood supply is derived
from both existing normal tissue and from newly generated
fibrovascular stromal reaction (Peterson, 1991). Although
rapidly growing transplantable rodent tumours do not
possess very much vascular smooth muscle, with much of
their blood supply derived from arteioles that enter the
tumour from surrounding normal tissue parenchyma, this is
probably not the case for many slow-growing human tumour
xenografts, spontaneous rodent tumours and clinical human
tumours. Thus, while the involvement of the surrounding
normal vasculature in supplying tumour blood flow may be
important, it may not be the only controlling factor.
The free radical gas nitric oxide (NO), which was pre-
viously identified as endothelium-derived relaxant factor
(Ignarro et al., 1987; Palmer et al., 1987), is generated by
conversion of L-arginine to L-citrulline in the presence of
nitric oxide synthase (NOS). The classification of NOS
isoforms has been based on Ca2+/calmodulin binding depen-
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dence, but this classification does not uniformly hold for all
isoforms. Constitutive, calcium-dependent, NO synthases are
found in the vascular (eNOS) and neuronal systems (bNOS)
and produce NO as part of a signal transduction mechanism.
In contrast, NOS induced by cytokines and endotoxin
(iNOS) provides for sustained release of NO as part of the
immune-mediated response, however both calcium-dependent
and -independent forms of iNOS have been described in
tumours (Sherman et al., 1993; Thomsen et al., 1994).
MeArg, a competitive inhibitor of both the calcium-depen-
dent and -independent forms of NOS, results in arteriolar
vasoconstriction and hypertension (Moncada et al., 1991).
NOS inhibition has recently been shown to reduce global
tumour and normal tissue perfusion, as indiectly determined
by inert gas washout (Andrade et al., 1992) and inorganic
phosphorus energy status (Wood et al., 1993, 1994). Whole-
organ measurements such as these, however, do not provide
information on heterogeneity of regional microvascular per-
fusion. As oxygen exchange within tumours occurs primarily
from venules (Secomb et al., 1993), and the oxygen diffiusion
distances from perfiused vessels within tumours are reported
to be less than 100gam (Dewhirst et al., 1994), direct observa-
tion of venules can provide a means to describe regional
changes in tumour microvascular perfusion that are relevant
to oxygen transport.
The purpose of this study was to examine the regional
microvascular effects of NOS inhibition, followed by L-
arginine, on tumour and surrounding tissue perfusion. Our
null hypothesis was that treatment with MeArg, followed by
L-arginine, would not lead to changes in diameter, red cell
velocity, length density or intermittent flow or stasis fre-
quency in tumour or control venules.
Material and
Animal model
Female Fischer 344 rats (Charles River Laboratories,
Raleigh, NC, USA), weighing 150-200 g, were surgically
implanted with cutaneous window chambers in order toNOSS-U. and bmp -
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visualise granulating subcutaneous tissue microvasculature
and to provide a substrate for tumour growth. Details of
chamber design and surgical technique have been published
elsewhere (Pappenfuss et al., 1979). Briefly, aseptic surgical
dissection of a 1.0-cm-diameter hole was made through
opposing surfaces of the dorsal skin flap, leaving a single
fascial plane with two or three artery-vein pairs. In tumour-
bearing preparations, a 0.1 mm3 piece of tumour (R3230Ac
mammary adenocarcinoma; (Hilf et al., 1965) was placed
onto the fascial plane at the time of surgery, whereas in
control chambers no tumour was implanted. Following sur-
gical implantation, animals were housed individually in an
environmental chamber maintained at 34C and 50% humid-
ity with continuous access to food and water. All prepara-
tions were used 9-11 days following surgery, at which time
the tumours were 3-4 mm in diameter. Animal use protocols
were approved by the Duke University Animal Care and Use
Committee.
Experimentalprotocol
The animals were anaesthetised with sodium pentobarbital
(40mg kg-', i.p.) and kept on a thermostatically controlled
blanket at a rectal temperature of 37C (Model 50-7503
Homeothermic Blanket, Harvard Bioscience, S. Natick, MA,
USA). The femoral artery and vein were canulated for
measurement of arterial blood pressure and i.v. infusion of
drugs. Arterial pressure waveforms (Gould P23XL, Gould
Instrument Systems, Cleveland OH, USA) and RBC velocity
were each digitised at 200 Hz and recorded to disk for later
analysis, with heart rate and mean arterial pressure deter-
mined from the pulsatile arterial waveform (AT-Codas,
Dataq Instruments, Akron, OH, USA). Rats were placed in
lateral recumbency on the microscope stage and the upper
window was removed. Earle's balanced Salt Solution (EBSS;
Gibco cat. no. 450-1 OOEB, Life Technologies, Grand Island,
NY, USA) bubbled with 5% CO2 in 95% N2, was superfused
across the surface at 1-2 ml min-'. The temperature of the
medium at the tissue surface approximated the normal skin
temperature of 32'C.
Selected fields of venules were observed in the tumour
centre, the hypervascular tumour periphery and in surround-
ing normal areas of granulating or healing subcutaneous
tissue away from the tumour. Post-capillary venules in
granulating tissue were also examined in non-tumour-bearing
control window chambers. Vessels were selected based on
optical contrast, focus and ability to determine RBC velocity.
The same vessels were observed before treatment (baseline)
and after treatment. After baseline observations, 50 M
MeArg (Calbiochem cat. no. 475886; in EBSS) was super-
fused across the exposed face of the tumour for 60 min and
measurements were repeated. L-Argiine (Calbiochem cat.
no. 1820; in EBSS), 200pM, was then superfused across the
chamber for an additional 60 min before masurements of
the same vessels were again made. The 50FM MeArg concen-
tration chosen was based on our preliminary studies, in
which 100ILM MeArg caused rapid and nearly complete
venular stasis, while the concentration of 200#AM L-arginine
was chosen to approximate its concentration in normal rat
plasma (Albina et al., 1990). The 60 min superfusion period
used in our experiments was based on findings of Kubes and
Granger (1992), where the onset of leucocyte adhesion in cat
mesentery venules in response to the NOS inhibitor N'3-nitro-
L-arginine methyl ester (50jiM) occurred between 15 and
25 min and reached a peak between 30 and 45 min.
Measurement ofvenular intraluminal diameter and RBC
velocity
Venule diameters and RBC velocities were performed using
video microscopy. Window chambers were transilluminated
with a 40 W tungsten source at 200 x on a Zeiss photomicro-
scope microscope stage (Carl Zeiss, Photomicroscope HI'
New York, NY, USA) equipped with a two-axis linear
measuring system (2-LM.5, Boeckeler Instruments, Tucson,
AZ, USA). Images were captured with a video camera (MTI
CCD-72, Dage-MTI, Michigan City, MI, USA) and recorded
on S-VHS tape for later analysis of vessel diameter (SVO-
9500MD, Sony Corporation of America, San Jose, CA,
USA). Identities and locations of individual vessels and exact
location of RBC velocity measurement were noted by tracing
the vascular bed for each region of interest onto acetate
sheets placed over the video-monitor and by noting the x-y
position of the field. Vessel diameter was measured at sites of
RBC velocity measurement by using a frame grabber (PC
Vison+, Imaging Technology, Woburn, MA, USA) and
image analysis software (Java, Jandel Scientific, Conte
Madera, CA, USA). The dual-window technique was used to
measure centerline RBC velocity (IPM model 204 Video
Analyzer and 102B Velocity Tracker, San Diego, CA, USA)
(Tompklins et al., 1974). RBC velocities are reported as
relative change from pretreatment baseline (see Statistical
analysis, below); division of RBC velocities by 1.6 to correct
for the Fahraeus effect (Baker and Wayland, 1974) was
therefore deemed unnecessary. Superimposition of a video-
timer signal (CTG-55 Video Timer, For.A Co., Los Angeles,
CA, USA) was used to document time of the videotape
record relative to treatment.
Determination ofvessel length density and intermittentflow
ratio
Videotaped segments of each experiment before treatment
(baseline), following treatment with MeArg, and again fol-
lowing treatment with L-argimne, were used to obtain the
morphometric index vessel length density (Chen et al., 1981)
and frequency of intermittent vascular flow and stasis. For
determination of vessel length density, a square grid was
superimposed over the video-screen and the number of inter-
sections between the grid and all vessels with RBC flow
during a 1 min period were counted. The number of grid
squares per video-field was 408. Typically the number of
intersections ranged from 150 to 300 per video-field. The
vessel length density in mm (mm-3) tissue was calculated
using:
Length density = ,,(4gtd)'
where N.,... = number of intersections between vessels
and gridlines, g = number of blocks in grid (408), d= length
of one grid square side corrected for magnification
(0.0193 mm) and t = measured depth of field through which
microvessels could be discerned (0.15 mm).
The frequency of venules demonstrating intermittent flow
or stasis, where intermittent flow was defined as stopped or
reversed flow for > 5s, was also determined from the
videotaped experiments. First, the total number ofvessels per
field was counted. A vessel was defined as a segment between
branch points. Vessels showing intermittent flow or stasis
were counted. Vessels which could not be positively identified
as having flow were noted separately. The percentage of
vessels demonstrating intermittent flow or stasis was cal-
culated as the number of vessels with intermittent flow and
flow stasis observed at any time during the 1 mim observation
interval divided by the total number of vessels in the field
minus the number of vessels with undetermined flow status.
Each vessel with intermittent flow was counted only once,
even if it stopped more than once during the 1 min interval;
the frequency of intermittency or stasis was not time weight-
ed. The percentage of venules demonstrating intermittent
flow or stasis was determined for both MeArg and L-arguune
treatment.
Statisticalanalysis
The relative change from baseline for each parameter was
determined by dividing treatment values by their correspond-
ing pretreatment value. Relative changes from baseline dia-
meter, RBC velocity, mean arterial pressure and heart rate
were assessed using a mixed-effects linear model (Crowder
and Hand, 1990). This model accounts for multiple measure-ments on each animal by utilising within-animal and
between-animal sources of vanration in the analysis. Means
and standard errors (and 95% confidence intervals) were
estimated from the models, which were fitted using the SAS,
STAT procedure PROC MIXED (SAS Institute. 1992). All
statistical tests of significance were based on two-sided tests
and a significance level of 0.05.
Results
Pretreatment diameter and RBC velocity [mean and standard
error (s.e.m.)] for control (n = 3) and tumour-bearing
(n = 15) window chamber experiments are summarised in
Table I. There were no pairwise differences in mean diameter
or mean RBC velocity between the three categories of
tumour preparation vessels, adjusted for multiple com-
parisons. Pretreatment diameter and RBC velocity for nor-
mal venules in tumour chambers were similar to those of
control chamber venules. Superfusion of MeArg and L-
argimnne had no systemic effects on mean arterial blood
pressure and heart rate (Tables II and III).
Superfusion of MeArg significantly reduced the diameters
of central tumour venules (13% reduction), peripheral
tumour venules (17% reduction) and normal venules near
tumours (16% reduction) and venules in control preparations
(30% reduction) (Figure 1. all P<0.05). There were no
significant pairwise differences between individual tumour
preparation vessel types with respect to relative diameter
changes following MeArg. Reduction of control preparation
venule diameters. however, was greater than for tumour-
bearing preparations (P = 0.02). Superfusion of L-argimnine
had a negligible effect in tumour preparations in restoring
diameters of tumour venules or normal venules near tumours
MM nOn and tumour perfusio
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to pretreatment levels (Figure 1, all P<0.05). Again, there
were no significant pairwise differences with respect to
relative diameter changes between individual tumour prep-
aration venules. In contrast, L-argimne completely restored
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Figwe I Relative change in microvessel diameter after 60 min
superfusion of MeArg followed by 60 min superfusion of L-
arginine. MeArg significantly reduced diameters for all types of
tumour preparation venules (O tumour centre; O, tumour peri-
phery: 0, normal near tumour) as well as for venules in control
(A) preparations (all P<0.05). Superfusion of L-arginine had
negligible restoring effect on tumour preparation venules, but
returned control venules to baseline diameter. Symbols represent
mean ± s.e.m.
Table I Baseline post-capillary venular blood flow parameters
Mfean velocitV
Number of Number of MUean diameter (mms-
Venule tipe Chamnber animals vessels (um) (s.e.m.) (s.e.m.)
Central tumour Tumour 8 39 32.2 (13.2) 0.55 (0.19)
Peripheral tumour Tumour 7 39 22.0 (4.2) 0.56 (0.28)
Normal. near tumour Tumour 6 36 34.7 (4.6) 0.32 (0.09)
Normal. no tumour Control 3 37 25.5 (18.5) 0.35 (0.37)
There are no significant pairwise differences (where P<0.05. adjusted for multiple comparisons) in
mean diameter or mean RBC velocity between vessels. Tumour-bearing chamber normal vessels were
not significantly different from control chamber normal vessels.
Table 11 Relative changes in mean arterial pressure after superfusion of MeArg
and L-arginine
MeArg L-arginine
Mean arterial blood Mean arterial blood
pressure change (95% pressure change (95%
Vessel Chamber CIJ CI)
Central tumour Tumour 0.95 (0.90-1.00) 0.93 (0.81-1.06)
Peripheral tumour Tumour 0.98 (0.94-1.03) 0.97 (0.85-1.09)
Normal. near tumour Tumour 0.96 (0.91-1.00) 0.89 (0.77-1.02)
Normal. no tumour Control 0.97 (0.88-1.07) 0.97 (0.75-1.19)
There were no significant differences in mean arterial pressure between treatment.
vessel type or tumour and control preparations.
Table III Relative changes in heart rate after superfusion of MeArg and
L-argilmne
MeArg L-Arginine
Heart rate change Heart rate change
V'essel Chamber (950% CI) (95% ClI
Central tumour Tumour 0.89 (0.83-0.95) 0.93 (0.88-0.99)
Peripheral tumour Tumour 0.97 (0.85-0.98) 0.96 (0.90-1.02)
Normal. near tumour Tumour 0.96 (0.89-1.02) 0.89 (0.84-0.95)
Normal. no tumour Control 0.90 (0.78-1.03) 0.92 (0.83-1.02)
There were no significant differences in heart rate between treatment. vessel type or
tumour and control preparations.
. .
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control preparation venule diameter to pretreatment levels.
Control venule diameters were greater following L-argimnne
than venule diameters of tumour preparations (P = 0.01).
MeArg superfusion significantly reduced RBC velocity in
control venules (66% reduction from baseline) and central
tumour venules (25% reduction) (Figure 2, both P<0.05).
RBC velocities for central tumour venules and peripheral
tumour venules (16% reduction) were both significantly
reduced compared with normal venules near tumours (17%
increase over baseline) (P<0.001 and P = 0.005 respectively).
MeArg reduced control venule RBC velocity more than in
tumour preparation venules (P = 0.004). L-arginine returned
RBC velocity toward pretreatment levels in control venules
(to 65% of baseline), but had negligible effect on RBC
velocity in peripheral tumour venules or normal venules near
tumours (Figure 2). Central tumour venule RBC velocity.
however, was further reduced from baseline following L-
arginine (to 61% of baseline; P<0.05), and remained
significantly lower than that of both peripheral tumour
venules and normal venules near tumours (P = 0.05 and
P = 0.03 respectively).
MeArg had no effect on length density in tumour prepara-
tion venules, although treatment tended towards reducing
length density in tumour preparation venules (Figure 3.
where P = 0.07 for central tumour venules and P = 0.08 for
both peripheral tumour venules and normal venules near
tumours). Length density decreased following L-arginine for
both tumour centre and peripheral tumour venules (P = 0.01
and P = 0.05 respectively).
MeArg superfusion significantly increased frequency of
intermittent vascular flow and stasis in central tumour vessels
(Figure 4, P = 0.03). MeArg did not affect intermittent vas-
cular flow and stasis frequency in peripheral tumour venules
and in normal venules near tumours. There were no differ-
ences in intermittent vascular flow and stasis frequency for
tumour preparation or control venules with L-arginine super-
fusion.
Disson
Similar to Andrade et al. (1992) and Wood et al. (1993,
1994), we have found that NOS inhibition reduces tumour
perfusion. However, our primary findings, that central
tumour venule perfusion is not restored by L-arginine follow-
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Figure 2 Relative change in microvessel RBC velocity after
60 min superfusion of MeArg followed by 60 min superfusion of
L-argimnine. MeArg reduced RBC velocity of control (A) and
tumour centre venules (0) from baseline (both P<0.05). L-
Arginine returned RBC velocity to baseline levels in tumour
periphery venules (O). normal venules near tumours (0) and
control preparation venules. but RBC velocity in tumour centre
venules remained significantly reduced from baseline (P<0.05).
Symbols represent mean ± s.e.m.
ing NOS inhibition. and that tumour presence blunts the
effect of NOS inhibition on surrounding vessels, have not
been previously reported. Taken together, these observations
provide insight into the mechanisms by which NO influences
tumour perfusion and suggest new ways to exploit the differ-
ences between tumour and normal vessels for potential thera-
peutic gain.
We have found that NOS inhibition reduces central
tumour perfusion and that L-arginine does not restore central
tumour flow. Relative flow can be calculated as the product
of cross-sectional area and velocity in order to illustrate the
interactive effects ofdiameter and RBC velocity. The effect of
MeArg superfusion was initially greater on the diameters and
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Figure 3 Relative change in vessel length density after 60 min
superfusion of MeArg followed by 60 min superfusion of L-
arginine. Although not statistically significant, MeArg treatment
tended towards reducing vessel length density in tumour venules
[P= 0.07. tumour centre: P= 0.08 for both tumour periphery
(O) and normal venules near tumours 0). Vessel length density
further decreased following L-argirnne for both tumour centre
(0) and peripheral tumour venules (P = 0.01 and P = 0.05
respectively). Symbols represent mean ± s.e.m. A. Control, no
tumour.
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Figure 4 Percentage of venules showing intermittent flow or
stasis after 60 min superfusion of MeArg followed by 60 min
superfusion of L-argimne. MeArg increased intermittent flow and
stasis in central tumour venules (Li) relative to baseline
(P = 0.03). MeArg did not affect intermittent vascular flow and
stasis frequency in peripheral tumour venules (O>) and in normal
venules near tumours (0) (P = 0.06 for both). L-Arginine
returned intermittent flow and stasis to baseline levels for all
vessel types. Symbols represent mean ± s.e.m. A. Control, no
tumour.
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Figure 5 Relative change in microvessel flow after 60 min super-
fusion of MeArg followed by 60 min superfusion of L-arginine.
MeArg reduced relative flow by 4300 in tumour centre (0) and
peripheral tumour venules (<O) and by 83% in control (A)
venules. L-Arginine restored peripheral tumour flow to the same
levels observed in normal venules near tumours (0). Flow in
central tumour venules continued to decrease in the presence of
L-arginine. The graph is provided to illustrate the interaction
between diameter and RBC velocitx.
RBC velocities of control venules. such that control venule
relative flow was reduced to 17% of baseline (Figure 5). In
tumour preparations. MeArg reduced both central tumour
and peripheral tumour venule relative flows to 57% of
baseline, and reduced relative flow in normal venules near
tumours to 83% of baseline (Figure 5). L-arginine completely
restored diameters and partially restored RBC velocities in
control venules, and increased flow in control venules to 64%
of baseline. In contrast, central tumour venule diameters and
RBC velocities remained decreased in the presence of L-
arginine, such that central tumour venule relative flow
decreased to 48% of baseline. Control venule length density
and frequency of intermittent flow and stasis were also less
affected by NOS inhibition and subsequent L-argirnne than
the same parameters in tumour venules. Thus, NOS inhibi-
tion initiates a decrease in central tumour perfusion, as
indicated by reductions in relative flow, length density and
increased frequency of intermittent flow and stasis. More
importantly, central tumour perfusion continues to be reduc-
ed following admim'stration of excess L-argilmne. These
findings indicate that reduction of vascular NO levels, fol-
lowed by normal tissue rescure with L-argimnne. can be used
to selectively reduce tumour perfusion.
An important question raised by our findings is how and
why tumour preparation venules demonstrate blunted dia-
meter and RBC velocity in response to inhibition of NOS as
compared with control venules? Our observation of blunted
vascular responses to NOS inhibition in tumour and sur-
rounding vasculature suggests that tumour presence can up-
regulate NOS activity in both tumour and distant normal
vessels. The mechanism by which this occurs probably
involves induction of iNOS activity in tumour and surround-
ing vasculature by tumour cytokines. Tumours have been
reported to produce NO (Radomski et al., 1991) and possess
NOS (Amber et al.. 1988). Poorly differentiated malignant
tumours possess increased levels of a Ca2+-dependent iNOS
(Thomsen et al.. 1994). while other tumours can be induced
by cytokines to produce a Ca2' calmodulin-independent
iNOS (Sherman et al.. 1993). Buttery et al. (1993) reported
that tumour presence induced a Ca-+ calmodulin-indepen-
dent NOS within the tumour neovasculature, but not within
tumour cells themselves, and concluded that tumours modu-
late the synthesis of NO in their vasculature by inducing
iNOS. In vascular endothelial cells. NO is produced by the
constitutive eNOS. However. cytokines such as interleukin 1p
(IL-1p) and tumour necrosis factor alpha (TNF-c) can cause
the induction of an iNOS in vascular smooth muscle (Schini
et al.. 1994). Studies are currently under way in our
laboratory to determine the specific identity of the cytokine
and to determine the distance from tumours over which this
blunting effect occurs. Methods specifically targeting iNOS or
tumour NO production could prove to be especially effective
means to modulate tumour blood flow.
Our finding that excess L-arginine did not reverse the
effects of MeArg on venule diameter and RBC velocity sug-
gests that maintenance of reduced blood flow following NOS
inhibition may rely on other factors. Wood et al. (1994)
reported reduced tumour blood flow lasting at least 6 h
following NoArg administration, returning to baseline levels
by 24 h. and speculated that this prolonged effect was due to
a lack of metabolism to L-arginine. NOS inhibition by
MeArg. however, is competitive and reversible by L-argirnne.
Thus, it is unlikely that the prolonged reduction in tumour
perfusion we observed was due to irreversible inhibition of
NOS. A more likely explanation for reduced tumour per-
fusion following NOS inhibition is endothelial damage and
thrombosis. Reduction of vascular NO enhances platelet
aggregation (Hogan et al.. 1988: Yao et al.. 1992). increases
leucocyte adhesion. extravasation and migration (Kubes et
al.. 1991) and increases leucocyte-dependent and -indepen-
dent microvascular permeability (Kubes and Granger. 1992).
Both platelet aggregation and leucocyte adhesion may con-
tribute to tumour vascular stasis by promoting endothelial
damage and microthrombus formation in the tumour or the
feeding vessels. Further studies will be required to determine
the mechanism by which NOS inhibition reduces tumour
blood flow.
The microvascular effects of substituted arginine NOS
inhibitors may be related to the experimental model employ.-
ed, the underlying vascular reactivity of the host tissues upon
which tumours are implanted and competition for substrate
within the preparations. For 10-40 um rabbit tenuissimus
muscle venules. Persson et al. (1990) reported diameter reduc-
tions similar to those we observed. to 82 ± 6% of baseline
with 100 gM MeArg: pretreatment with 1 mM L-arginine
inhibited the venular diameter reduction. Kubes et al. (1991).
however, observed no venular diameter reduction in 30 gm
cat mesenteric venules superfused with either 100 gM MeArg
or 1I00 jM NoArg. We chose superfusion to avoid systemic
cardiovascular effects. however vessel absorption by this
route. and thus the intensity of observed effects, may differ
from systemic administration. Although we superfused L-
argiine in a concentration similar to that reported for nor-
mal rat plasma (Albina et al.. 1990). it is possible that we did
not achieve physiological intracellular levels of L-arginine.
This could be a reason for the partial reversal of RBC
velocity we observed in control preparation venules.
In addition. inflammatory cells and activated macrophages
may,. through production of arginase (Albina et al.. 1990;
Benninghoff et al.. 1991). compete for available L-arg'nine
such that higher than physiological concentrations of L-
arginine may be required to completely reverse NOS inhibi-
tion. L-Arginine can be metabolised either to citrulline in the
presence of the calcium-dependent and -independent forms of
NOS. producing NO in the process. or to ornithine and urea
in the presence of arginase. Levels of arginine in wound fluid
from 10-day-old granulating sponge implants are less than
50 M. as compared with 225 jm in normal rat plasma
(Albina et al.. 1990); wound fluid ornithine and arginase
activity are highest in this model 10 days following sponge
implantation as well, suggesting that competition between
macrophages and the vascular endothelium for L-arginine
mav be a factor in granulation tissue models. Further. based
on Michaelis-Menten kinetics. concentrations of MeArg
higher than 50 gM may be required for maximal inhibition of
NOS (Pollock et al.. 1991). Optimisation of NOS inhibitor
and L-arginine concentration and kinetics will be necessary in
order to fully exploit this potential therapy.
We have observed that inhibition of NOS reduces both
1173NOS inNbi6o and tumour pefusion
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tumour and normal microvascular perfusion and that subse-
quent administration of L-argimne can restore normal tissue,
but not tumour, perfusion. Tumours may influence their own
microvascular perfusion as well as perfusion in surrounding
tissues by inducing NOS production. Tumour NOS inhibi-
tion followed by normal tissue rescue with administration of
L-argirmne may provide a novel means of achieving the
therapeutic goal of selective tumour hypoxia.
Abbreviatioas NO, nitric oxide; NOS. nitric oxide synthase; eNOS.
endothelial NOS; bNOS. neuronal or brain NOS; iNOS. inducible
NOS: MeArg. VG-monomethyl-L-arginine: NoArg. N-nitro-L-
arginine: EBSS. Earle's balanced salt solution; IL. interleukin; TNF.
tumour necrosis factor.
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